News
FATE
4.300
-5.29%
-0.240
Fate Therapeutics Currently Down 11 Consecutive days, on Track for Record Losing Streak -- Data Talk
Fate Therapeutics, Inc. Is currently at $4.36, down $0.18 or 3.96%. Down 14 of the past 15 days. Down 11 consecutive days; down 35.5% over this period. Down 96.29% from its all-time closing high of $117.40.
Dow Jones · 22h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)
TipRanks · 1d ago
Fate Therapeutics Currently Down 10 Consecutive Days, on Pace for Longest Losing Streak Since December 2022 -- Data Talk
Fate Therapeutics, Inc. Is currently at $4.58, down $0.21 or 4.29%. Down 13 of the past 14 days; down 10 consecutive days. Down 96.1% from its all-time closing high of $117.40.
Dow Jones · 1d ago
Fate Therapeutics To Present FT819 Proof-Of-Concept Data For B cell-Mediated Autoimmune Diseases At ASGCT Annual Meeting
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases to be Highlighted in FT819 Phase 1 Study of CAR T-cell Therapy for Systemic Lupus Erythematosus. Patients will be enrolled in a clinical trial to evaluate the safety and effectiveness of the therapy.
Benzinga · 2d ago
FATE THERAPEUTICS ANNOUNCES PRESENTATION OF FT819 PROOF-OF-CONCEPT DATA FOR B CELL-MEDIATED AUTOIMMUNE DISEASES AT ASGCT ANNUAL MEETING
Reuters · 2d ago
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
NASDAQ · 2d ago
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
NASDAQ · 2d ago
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
NASDAQ · 2d ago
Weekly Report: what happened at FATE last week (0415-0419)?
Weekly Report · 3d ago
Novartis (NVS) to Report Q1 Earnings: What to Expect?
NASDAQ · 5d ago
What's in Store for Biogen (BIIB) This Earnings Season?
NASDAQ · 5d ago
Fate Therapeutics files to sell 3.64M shares for holders
Seeking Alpha · 6d ago
Weekly Report: what happened at FATE last week (0408-0412)?
Weekly Report · 04/15 11:22
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
NASDAQ · 04/12 13:09
Where Fate Therapeutics Stands With Analysts
F Fate Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. 6 analysts have set 12-month price targets for FateTherapeutics with an average target of $7.33. Analysts have expressed a mix of bullish and bearish views on the company.
Benzinga · 04/11 14:00
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)
TipRanks · 04/11 10:20
Needham Reiterates Hold on Fate Therapeutics
Benzinga · 04/11 10:09
FATE, ALPN and RLAY are among after hour movers
On the Move FATE, ALPN and RLAY are among after hour movers. Rallybio Corporation and Alpine Immune Sciences are among the biggest gainers. Performant Financial and NioCorp Developments are the biggest losers in the after hour.
Seeking Alpha · 04/10 21:20
12 Health Care Stocks Moving In Wednesday's After-Market Session
Rallybio shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by 10.52% during the session.
Benzinga · 04/10 20:31
Weekly Report: what happened at FATE last week (0401-0405)?
Weekly Report · 04/08 11:27
More
Webull provides a variety of real-time FATE stock news. You can receive the latest news about Fate Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.